5-HT6 receptor antagonists. Design, synthesis, and structure-activity relationship of substituted 2-(1-methyl-4-piperazinyl)pyridines
- Bioorg Med Chem Lett. 2023 Oct 6:96:129497. doi: 10.1016/j.bmcl.2023.129497.
- 1. Ryvu Therapeutics S.A., Sternbacha Street 2, 30-394 Kraków, Poland. Electronic address: [email protected].
- 2. Ryvu Therapeutics S.A., Sternbacha Street 2, 30-394 Kraków, Poland.
- 3. Orion Corporation, Orion Pharma, Orionintie 1A, 02200 Espoo, Finland.
- 4. Department of Behavioral Neuroscience and Drug Development, Maj Institute of Pharmacology Polish Academy of Sciences, 12 Smętna Street, 31-343 Kraków, Poland.
In this study, we present the discovery and pharmacological characterization of a new series of 6-piperazinyl-7-azaindoles. These compounds demonstrate potent antagonism and selectivity against the 5-HT6 receptor. Our research primarily focuses on optimizing the lead structure and investigating the structure-activity relationship (SAR) of these compounds. Our main objective is to improve their activity and selectivity against off-target receptors. Overall, our findings contribute to the advancement of novel compounds targeting the 5-HT6 receptor. Compound 29 exhibits significant promise in terms of pharmacological, physicochemical, and ADME (Absorption, Distribution, Metabolism, and Excretion) properties. Consequently, it merits thorough exploration as a potential drug candidate due to its favorable activity profile and successful outcomes in a range of in vivo experiments.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: 5-HT ReceptorResearch Areas: Others